Medical radiotheranostics, a revolutionary concept in cancer care, integrates diagnosis and therapy, enhancing the precision and efficacy of treatments. This innovative approach utilises radiolabelled compounds that can both image and treat malignancies, offering a dual benefit that has significantly advanced the field of nuclear medicine.
The term ‘radiotheranostics’ combines ‘radiotherapy’ and ‘diagnostics’, reflecting its dual functionality. It involves the use of specific molecules that bind to cancer cells and are tagged with radioactive isotopes. These isotopes are carefully chosen so that their emitted radiation can be detected by imaging techniques such as Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT), allowing for precise tumour localisation. Following imaging, the same radioactive isotopes deliver targeted radiation therapy, destroying the cancer cells while minimising damage to surrounding healthy tissue.
One of the pivotal elements of radiotheranostics is the selection of appropriate targets on cancer cells, such as receptors or antigens that are overexpressed in certain tumour types. For example, the prostate-specific membrane antigen (PSMA) is used as a target in prostate cancer. Radiolabelled molecules that bind to PSMA can be visualised to assess the extent and location of the cancer and then used to deliver lethal doses of radiation directly to the tumour cells.
This targeted approach offers several advantages over traditional methods. Firstly, it allows for the assessment of the biodistribution of the radiopharmaceutical, ensuring that it accumulates sufficiently within the tumour before commencing therapeutic radiation. This leads to a more tailored treatment plan based on the individual’s specific disease presentation, which can result in improved efficacy and reduced side effects. Additionally, radiotheranostics can provide vital information on tumour response early in the treatment course, enabling adjustments to be made if necessary.
Another significant benefit of radiotheranostics is its potential in treating metastatic diseases, which are often difficult to manage with conventional therapies. For instance, Lutetium-177 PSMA therapy has shown promising results in patients with metastatic castration-resistant prostate cancer, providing a new lifeline where previous therapies have failed.
The future of medical radiotheranostics looks promising as research continues to evolve. New targets are being explored, and advances in molecular biology and imaging technology are likely to expand the range of cancers that can be treated with this method. Moreover, developing novel radiolabelled compounds that can be used for diagnostic and therapeutic purposes is set further to enhance the effectiveness and safety of cancer treatments, heralding a new era in personalised medicine. As this field grows, it holds the potential to significantly alter the landscape of cancer treatment, offering hope to those battling this complex disease.
You are here:
home » medical radiotheranostics »
By
| 4 minutes of readingTargeting Blood Cancers: The Role of Iodine-131 Apamistamab in Revolutionising Treatment for AML and Beyond.
The Role of Iodine-131 Apamistamab for Acute Myeloid Leukaemia Read Article »
By
| 4 minutes of readingWorld Theranostics Day honours Dr. Hertz’s groundbreaking radioiodine therapy, transforming disease treatment globally since 1941.
Celebrating World Theranostics Day Honoring Saul Hertz Read Article »
By
| 4 minutes of readingIodine-131 Monoclonal Antibody 81C6 specifically targets glioma cells by honing in on the tenascin protein.
Iodine-131 Monoclonal Antibody 81C6 Targets Glioma Cells Read Article »
By
| 4 minutes of readingHolmium-166 Phytate, initially developed for chronic synovitis, has shown significant promise in phase I/II clinical trials.
Holmium-166 Phytate Offers a Promising Treatment Option for Chronic Synovitis Read Article »
By
| 4 minutes of readingHolmium-166 Chitosan, a groundbreaking radiopharmaceutical, offers new hope in treating hepatocellular carcinoma with targeted therapy.
Holmium-166 Chitosan in Radiopharmaceutical Cancer Treatment Read Article »
By
| 4 minutes of readingHolmium-166 microspheres, by delivering localized radiation, significantly enhance the therapeutic approach to inoperable liver cancer treatment.
The Role and Impact of Holmium-166 Microspheres in Brachytherapy Read Article »
By
| 4 minutes of readingCopper-67 SARTATE emerges as a groundbreaking radiopharmaceutical in targeted cancer therapy, showcasing promising clinical trial results.
Unlocking the Potential of Copper-67 SARTATE in Targeted Radiopharmaceutical Therapy Read Article »
By
| 4 minutes of readingCopper-67 SARbisPSMA offers new hope in targeting and treating prostate cancer with precision and effectiveness.
Copper-67 SARbisPSMA New Frontier in Prostate Cancer Treatment Read Article »
By
| 4 minutes of readingCopper-64 Diasparagine offers a promising breakthrough in targeting and treating aggressive brain tumours like glioblastoma.
By
| 3 minutes of reading213Bi-Lintuzumab demonstrated efficacy in AML treatment, offering a targeted approach with manageable side effects, yet development paused.
Bismuth-213 Lintuzumab: A Promising Treatment for Acute Myeloid Leukaemia Read Article »
By
| 4 minutes of reading213Bi-DOTATOC offers potent, targeted alpha therapy for tumours, advancing treatment with precision and reduced systemic toxicity.
Bismuth-213 DOTATOC: A Promising Alpha-Labelled Analogue for Tumour Therapy Read Article »
By
| 4 minutes of reading211At-MX35-F(ab’)2 shows promise in treating ovarian cancer through targeted therapy in ongoing clinical trials.
The Potential of Astatine-211-MX35-F(ab’)2 in Ovarian Cancer Treatment Read Article »
By
| 16 minutes of readingTheragnomics melds theranostics and radiomics, promising targeted cancer therapies with improved outcomes through precision diagnostics and treatment adaptation.
Combining Theranostics and Radiomics: The Emergence of Theragnomics Read Article »
By
| 4 minutes of readingThe innovative 211At-MABG targets rare tumours like malignant pheochromocytoma and paragangliomas, promising a new era in treatment.
Astatine-211 MABG in Malignant Pheochromocytoma and Paragangliomas Read Article »
By
| 19 minutes of readingRadiotheranostics merges diagnostics and therapy, offering targeted cancer treatment amidst challenges like high costs and need for specialised facilities.
Revolutionising Cancer Care: The Promise and Challenges of Radiotheranostics Read Article »
By
| 20 minutes of readingThorium-227 emerges in nuclear medicine, revolutionizing cancer treatment through precise, effective radiotheranostic and therapeutic applications.
The Breakthrough Role of Thorium-227 in Theranostic Radiopharmaceuticals Read Article »
By
| 3 minutes of readingNeuroblastoma Targeting Agents offer innovative diagnostic and therapeutic options, revolutionizing treatment with precise targeting and efficacy.
Neuroblastoma Targeting Agents: An Insight into Diagnostic and Therapeutic Advances Read Article »
By
| 3 minutes of readingTechnetium-99m and Radium-223 are pivotal in managing bone metastases, enhancing both diagnostic accuracy and therapeutic efficacy.
By
| 3 minutes of readingGallium-68 and Lutetium-177 labelled Girentuximab mark a breakthrough in diagnosing and treating hepatocellular carcinoma.
Targeting Hepatocellular Carcinoma: The Emerging Role of Girentuximab Read Article »
By
| 4 minutes of readingUtilising CXCR4 targeting agents with labelled ligands marks a breakthrough in treating haematological malignancies effectively.
CXCR4 Targeting Agents for Haematologic Malignancies Read Article »
By
| 4 minutes of readingFolate Receptor Targeting Agents revolutionise cancer diagnosis and treatment with Fluorine-18 and Rhenium-188 labelling.
Folate Receptor Targeting Agents: Pioneering Progress in Cancer Diagnosis and Therapy Read Article »
By
| 4 minutes of readingEstrogen receptor targeting agents, including Fluorine-18 and Iodine-131 analogues, revolutionise breast cancer diagnostics, therapeutics, and personalised patient management.
By
| 4 minutes of readingFAPI revolutionises oncology with precise Gallium-68 diagnostics and targeted Lutetium-177 therapy for cancer.
By
| 4 minutes of readingSomatostatin Receptor Targeting Agents offer groundbreaking diagnostic and therapeutic solutions for neuroendocrine tumour management and care.
By
| 5 minutes of readingPSMA targeting agents revolutionise prostate cancer care with precise diagnostics and targeted therapeutic approaches.
By
| 4 minutes of reading211At-BC8-B10, targeting CD45 in leukemia, combines BC8 antibody with Astatine-211, showing promising clinical trials.
Astatine-211 BC8-B10: A Promising Radioimmunoconjugate for Leukaemia Treatment Read Article »
By
| 4 minutes of readingAstatine-211 in radiotheranostics offers targeted, effective cancer treatment, but faces production and safety challenges.
Astatine-211 Radiotheranostics: A New Era in Cancer Treatment Read Article »
By
| 3 minutes of reading211At-81C6-mAb, targeting tenascin in brain tumours, shows extended survival but needs further funding for development.
Astatine-211 81C6-mAb: A Breakthrough in Brain Tumour Treatment with Alpha Radiation Read Article »
By
| 4 minutes of reading225Ac-RYZ101 offers promising GEP-NET treatment, targeting tumours with alpha particles via somatostatin receptor-specific edotreotate.
By
| 4 minutes of reading225Ac-Rosopatamab, targeting metastatic prostate cancer, combines monoclonal antibodies with alpha radiation, showing promise in early trials.
Actinium-225 Rosopatamab: A Breakthrough in Metastatic Prostate Cancer Treatment Read Article »
By
| 4 minutes of reading225Ac-PSMA-617 revolutionises prostate cancer treatment, offering targeted, effective therapy with promising clinical trial results.
Actinium-225 PSMA-617: Revolutionising Prostate Cancer Treatment Read Article »
